Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | LDHA | P00338 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 7/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 7/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799083 | 1.00 | CYP11B1 (0.47) | CYP11B1CYP11B2LDHALTA4HCYP4F2 | |
| SCHEMBL23319886 | 0.86 | HAO1 (0.41) | CYP4F2CYP4A11HAO1 | |
| SCHEMBL23319901 | 0.85 | MAP4K4 (0.39) | CYP11B1CYP11B2CYP4F2CYP4A11HPGDS | |
| SCHEMBL25464994 | 0.84 | CYP4F2 (0.37) | CYP11B1CYP11B2CYP4F2CYP4A11HAO1 | |
| SCHEMBL25464175 | 0.84 | CYP4F2 (0.37) | CYP11B1CYP11B2CYP4F2CYP4A11HAO1 | |
| SCHEMBL21296854 | 0.84 | HAO1 (0.44) | HAO1TP53HPGDS | |
| SCHEMBL21296849 | 0.84 | TACR3 (0.44) | HAO1TP53HPGDS | |
| SCHEMBL29799073 | 0.84 | TACR3 (0.44) | HAO1TP53HPGDS | |
| SCHEMBL25463526 | 0.83 | HAO1 (0.34) | CYP11B2CYP4F2CYP4A11HAO1HPGDS | |
| SCHEMBL21296882 | 0.80 | HAO1 (0.44) | HAO1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | CYP11B1 856/4885CYP11B2 883/4885LDHA 490/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | CYP11B1 856/4885CYP11B2 883/4885LDHA 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.